

AAT-ADPD 2020

Legend:

PLENARY SESSION	SHORT ORAL POSTERS
FORUM DISCUSSION	SPONSORED SESSION
SYMPOSIUM	OTHER EVENT
SATELLITE SYMPOSIUM	

Wednesday April 1, 2020					
09:00 - 16:45	DATA SCIENCE AND DIGITAL HEALTH FOR NEURODEGENERATIVE DISORDERS				
Thursday, April 2, 2020					
	Hall E	Hall F1	Hall F2	Hall N	Hall M
09:30 - 10:00	PLENARY 1: ALZHEIMER'S DRUG DEVELOPMENT PIPELINE: NOVEL TARGETS AND INNOVATIVE APPROACHES				
10:00 - 10:30	PLENARY 2: THE CONTRIBUTION OF TDP43 TO COGNITIVE DISORDERS OF LATE LIFE				
10:30 - 11:00	SPECIAL LECTURE: RESULTS OF THE DIAN-TU PREVENTION TRIAL OF SOLANEZUMAB AND GANTENERUMAB IN DOMINANTLY INHERITED AD				
11:00 - 13:00	IMMUNOTHERAPY 1	TAU IMAGING 1	SYNUCLEINOPATHIES: DIAGNOSTIC AND PROGNOSTIC MARKERS	IMAGING & BIOMARKERS FOR DIAGNOSIS AND CLASSIFICATION: NGF, RETINAL THICKNESS AND MORE	
14:00 - 16:00	SPONSORED SYMPOSIUM 1 - not included in main event CME/CPD credit				
16:00 - 16:50	FORUM DISCUSSION : RESULTS OF THE DIAN-TU PREVENTION TRIAL OF SOLANEZUMAB AND GANTENERUMAB IN DOMINANTLY INHERITED AD				
16:30 - 18:30	FORUM DISCUSSION 1: APPLICATIONS OF NEUROPSYCHOLOGY, PET, MRI, EEG, AND CSF FOR DIAGNOSIS AND ASSESSMENT OF TREATMENT EFFECTS <small>(17:00 - 18:00)</small>	CLINICAL ASPECTS OF PD AND LEWY BODY DISEASE	APOE & LIPOPROTEIN-BASED THERAPEUTIC TARGETS	SYNUCLEIN, ABETA AND NEUROTOXICITY: MECHANISTIC ASPECTS	AD: FROM ANIMAL MODELS TO TREATMENT STRATEGIES
	IMMUNOTHERAPY 2 <small>(17:35 - 18:35)</small>				
18:00 - 19:00	Meet the Professors: Irena Rektorova and Willaim Jagust				

Friday, April 3, 2020					
	Hall E	Hall F1	Hall F2	Hall N	Hall M
08:00 - 08:30	PLENARY 3				
08:35 - 10:35	LESSONS LEARNED FROM CLINICAL TRIALS IN AD	PATHOLOGICAL HALLMARKS IN AD: FROM KEY PLAYERS TO CROSS-TALK	MICROGLIA RESPONSE DURING THE COURSE OF AD AND PD: A TARGET FOR THERAPY?	AD & SYNUCLEINOPATHIES: CRITERIA FOR DIAGNOSIS AND CLASSIFICATION GAINING INSIGHTS IN DEMENTIA VIA IMAGING, BIOMARKERS AND EEG	SHORT ORAL of Poster Presentations 1 (08:35 - 10:29)
11:05 - 13:00	SPONSORED SYMPOSIUM 2- not included in main event CME/CPD credit				
14:30 - 16:40		IMMUNOTHERAPY 3	INFLAMMATION, MICROGLIA AND IMMUNE RESPONSE: CAUSE OR CONSEQUENCE OF NEURODEGENERATION?	PLASMA AND CSF BIOMARKERS IN AD: WHAT DO THEY TELL US? SESSION I	TREATING AD: ALTERNATIVES TO IMMUNOTHERAPY I
	SPONSORED SYMPOSIUM 3- not included in main event CME/CPD credit (15:40 - 16:40)				
16:00 - 17:00	FORUM DISCUSSION 2: TRANSLATIONAL DRUG DISCOVERY IN PD/ LBD PHASE I-III	Meet the Professors: Guojun Bu, Agneta Nordberg and Kaj Blennow			
17:10 - 19:10	PLASMA AND CSF BIOMARKERS IN AD: WHAT DO THEY TELL US? SESSION II	GENETIC ASPECTS IN AD, LBD AND PD	FUTURE DIRECTIONS IN THE TREATMENT OF SYNUCLEINOPATHIES	AD THERAPY REVISITED – CAN WE OPTIMIZE TREATMENT?	FUNDING OPPORTUNITIES FOR DRUG DEVELOPMENT IN AD AND PD
17:15 - 18:15	Meet the Professors: Britt Mollenhauer and Walter Koroshetz				

Saturday, April 4, 2020					
	Hall E	Hall F1	Hall F2	Hall N	Hall M
08:30-09:00	PLENARY 4: WORLD-WIDE FINGERS AND THE NEXT GENERATION OF CLINICAL TRIALS IN ALZHEIMER'S DISEASE				
09:05-11:05	DYSFUNCTION OF THE CHOLINERGIC SYSTEM IN AD, PD AND AGING	BLOOD BRAIN-BARRIER, MICROBLEEDS, DEMENTIA AND CEREBRAL AMYLOID ANGIOPATHY	HOW CHANGES IN BRAIN ARCHITECTURE AND FUNCTION PREDICT THE RATE OF COGNITIVE DECLINE	EMERGING THERAPIES FOR PD RELATED TO GLUCOCEREBROSIDE MUTATIONS: FROM BENCH TO FIRST IN HUMAN TRIAL	SHORT ORAL of Poster Presentations 2 (08:35 - 10:29)
14:30 - 16:30		DO SEX AND GENDER MAKE A DIFFERENCE IN AD AND PD? (14:30 - 16:30)	ALS, FTD AND PSP: DIAGNOSIS AND TREATMENT (14:30 - 16:30)	IMAGING AND BIOMARKERS IN AD, PD, LBD (14:30 - 16:30)	SYNUCLEINOPATHIES AND TAUOPATHIES: PATHOLOGICAL CORRELATES (14:30 - 16:30)
	SPONSORED SYMPOSIUM 4- not included in main event CME/CPD credit (15:35 -16:45)				
16:00 - 17:00	Meet the Professors: Hermona Soreq, Michael Heneka and Sam Sisodia				
17:00 - 18:15	FORUM DISCUSSION 3: TRANSLATIONAL DRUG DISCOVERY IN AD: LEARNING FROM FAILURES AND SUCCESSES				
17:10- 19:10	MICROBIOME AND IMMUNE MECHANISMS: ARE WE READY FOR A THERAPEUTIC APPROACH?	LRRK2 AND A-SYNUCLEIN FUNCTIONS AND TARGETED THERAPY IN PD	NON-PHARMACOLOGICAL AND DRUG REPURPOSING IN AD AND PD	NOVEL IMAGING STRATEGIES AND BIOMARKERS OF SYNAPTIC FUNCTION AND COGNITIVE RESERVE IN AD	AGING, PD, MCI: CLINICAL FEATURES

Sunday, April 5, 2020					
	Hall E	Hall F1	Hall F2	Hall N	Hall M
08:00 -08:30	PLENARY 5: DIGITAL TECHNOLOGIES, BRIGHT SHINY OBJECTS AND THE FUTURE OF CLINICAL TRIALS IN PARKINSON'S DISEASE				
08:35 -10:35	FUTURE DIRECTIONS IN THE TREATMENT OF PD, LBD	TREATING AD: ALTERNATIVES TO IMMUNOTHERAPY II	IMAGING AND BIOMARKERS IN LBD AND PD	TREM2 AND MICROGLIA: TARGETING INFLAMMATION IN AD	TRANSLATIONAL R&D IN TAUOPATHIES AND SYNUCLEINOPATHIES
11:05 - 13:05	NEUROTROPHINS , HEMATOPOIETIC FACTORS AND MICRO-RNA: TARGETS FOR THERAPIES OF AD AND PD	TRANSLATIONAL R&D: IN VITRO AND IN VIVO MODELS IN AD	DZNE SYMPOSIUM	APOE, DIABETES AND COGNITIVE FUNCTION	